A Randomized Phase II Trial of Nivolumab and Ipilimumab Compared to Nivolumab Monotherapy in Patients With Deficient Mismatch Repair System Recurrent Endometrial Carcinoma
Latest Information Update: 06 Jan 2025
Price :
$35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Nivolumab biosimilar Amgen (Primary)
- Indications Carcinoma; Endometrial cancer
- Focus Therapeutic Use
- 13 Sep 2024 Status changed from suspended to recruiting.
- 07 Aug 2024 Status changed from recruiting to suspended. (Other - Safety Analysis)
- 26 Sep 2023 Planned number of patients changed from 25 to 90.